Does Rallies show Form 4 insider transactions for MBRX?

Yes. Rallies tracks MBRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MBRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MBRX. It does not provide personalized investment advice.

MBRX (Moleculin Biotech, Inc.) Stock Analysis - Insider Trades

Moleculin Biotech, Inc. (MBRX) is a publicly traded Healthcare sector company. As of May 21, 2026, MBRX trades at $2.30 with a market cap of $11.15M and a P/E ratio of -0.08. MBRX moved +0.00% today. Year to date, MBRX is -40.00%; over the trailing twelve months it is -90.45%. Its 52-week range spans $1.79 to $91.25. Analyst consensus is strong buy with an average price target of $21.00. Rallies surfaces MBRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MBRX stock inside the company?

Recent MBRX insider activity includes Foster Jonathan P. bought 270.27K, KLEMP WALTER V bought 675.67K, Foster Jonathan P. bought 28.99K, George Robert E. bought 14.49K, and KLEMP WALTER V bought 188.40K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MBRX Key Metrics

Key financial metrics for MBRX
Metric	Value
Price	$2.30
Market Cap	$11.15M
P/E Ratio	-0.08
EPS	$-28.42
Dividend Yield	0.00%
52-Week High	$91.25
52-Week Low	$1.79
Volume	74
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-33.56M
Gross Margin	0.00%

Recent MBRX Insider Trades

Foster Jonathan P. bought 270.27K (~$100.00K) on Jun 23, 2025.
KLEMP WALTER V bought 675.67K (~$250.00K) on Jun 23, 2025.
Foster Jonathan P. bought 28.99K (~$20.00K) on Dec 26, 2023.
George Robert E. bought 14.49K (~$10.00K) on Dec 26, 2023.
KLEMP WALTER V bought 188.40K (~$130.00K) on Dec 26, 2023.

Latest MBRX News

Moleculin Reports No Cardiotoxicity in 90-Patient Annamycin AML Safety Review — May 12, 2026
Moleculin Biotech Secures Hong Kong Patent for Annamycin Through June 2040 — May 8, 2026
Moleculin to Present Annamycin Cardiac Safety Data at 2026 ASCO Poster Session — Apr 21, 2026
Moleculin Highlights Annamycin’s Non-Cardiotoxic Profile to Support Phase 3 AML Trial — Apr 7, 2026
FDA Eases Cell Therapy Rules as Market Forecast Hits $14B by 2035 — Mar 27, 2026

MBRX Analyst Consensus

3 analysts cover MBRX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.00.

Common questions about MBRX

Who is trading MBRX stock inside the company?: Recent MBRX insider activity includes Foster Jonathan P. bought 270.27K, KLEMP WALTER V bought 675.67K, Foster Jonathan P. bought 28.99K, George Robert E. bought 14.49K, and KLEMP WALTER V bought 188.40K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MBRX?: Yes. Rallies tracks MBRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MBRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MBRX. It does not provide personalized investment advice.